Author: Norman Peter
Publisher: Informa Healthcare
ISSN: 1354-3776
Source: Expert Opinion on Therapeutic Patents, Vol.14, Iss.9, 2004-09, pp. : 1345-1349
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
This article is the first of a series that examines the patenting policy of the leading genomics companies. Celera is a public company, although it is a subsidiary of Applera Corp., and was founded in 1998 to exploit the sequence of the human genome by licensing its genomic databases and patents. In 2001 its strategy changed with the acquisition of the biotechnology company Axys Pharmaceuticals, and Celera has evolved into a biotechnology company seeking to exploit small-molecule therapeutics and antibodies in addition to its genomic databases. Analysis of its patenting activity indicates that the rate of filing of genomic applications peaked in 2002, whilst there is little evidence of the acquisition of Axys stimulating patent filings from that group.
Related content
Current Drug Targets, Vol. 8, Iss. 10, 2007-10 ,pp. :
Costs and Benefits of Genomics Patents
American Journal of PharmacoGenomics, Vol. 4, Iss. 5, 2004-01 ,pp. :
Technology: methodologies in genomics and proteomics
International Journal of Pharmaceutical Medicine, Vol. 15, Iss. 2, 2001-04 ,pp. :
Functional Genomics Approaches in Arthritis
By Attur M.G. Dave M.N. Amin A.R.
American Journal of PharmacoGenomics, Vol. 4, Iss. 1, 2004-01 ,pp. :
Trends in Pharmacological Sciences, Vol. 19, Iss. 5, 1998-05 ,pp. :